# ScoreItem: ECG - Intervalo PR

**ID:** `019bf31d-2ef0-7beb-a8e2-52d70d467241`
**FullName:** ECG - Intervalo PR (Exames - Imagem)
**Unit:** ms

**Preparation Metadata:**
- Quality Grade: **FAIR**
- Total Chunks: 30 de 15 artigos
- Avg Similarity: 0.480

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7beb-a8e2-52d70d467241`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7beb-a8e2-52d70d467241",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** ECG - Intervalo PR (Exames - Imagem)
**Unidade:** ms

**30 chunks de 15 artigos (avg similarity: 0.480)**

### Chunk 1/30
**Article:** 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay (2018)
**Journal:** Circulation
**Section:** abstract | **Similarity:** 0.564

Comprehensive clinical practice guideline for the evaluation and management of patients with bradycardia and cardiac conduction delay. The guideline provides evidence-based recommendations for diagnosis using 12-lead ECG and external ambulatory electrocardiographic monitoring, evaluation of symptomatic bradycardia, and management strategies including pharmacological and device therapy. Bradycardia is defined as heart rate < 60 bpm, with clinical significance determined by patient symptoms and hemodynamic stability.

---

### Chunk 2/30
**Article:** Aula Afonso Salgado - Sistema nervoso aut√¥nomo (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.561

ia√ß√£o descrito inclui:

- Exame realizado preferencialmente pela manh√£, em jejum, evitando a ingest√£o de medicamentos naquele momento (pois alteram a leitura).  
- Repeti√ß√£o do exame em **3 a 5 ocasi√µes** em condi√ß√µes semelhantes, para obter dados de ‚Äúpadr√£o ouro‚Äù (maior confiabilidade).  

A partir do ECG, softwares especializados analisam a VFC tanto no **dom√≠nio do tempo** quanto no **dom√≠nio da frequ√™ncia**:

- No dom√≠nio do tempo, o par√¢metro mais citado √© o **SDNN** (desvio padr√£o dos intervalos NN), que √© uma raiz quadrada aplicada √† distribui√ß√£o dos intervalos.  
- SDNN mais alto indica maior variabilidade; SDNN baixo indica rigidez do ritmo, associada a pior progn√≥stico.

No dom√≠nio da frequ√™ncia, embora Afonso n√£o detalhe numericamente, ele indica o uso de t√©cnicas matem√°ticas como:

- **R√°pida transformada de Fourier (FFT)**,  
- **wavelet transform**,  
- **ritmogramas** (conceito de origem russa).

---

### Chunk 3/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.522

atherosclerosis:Resultsfromaprospective,parallel-groupcohortstudy.Clin.Chim.Acta2015,447,16‚Äì22.[CrossRef]101.Hijazi,Z.;Lindahl,B.;Oldgren,J.;Andersson,U.;Lindb√§ck,J.;Granger,C.B.;Alexander,J.H.;Gersh,B.J.;Hanna,M.;Harjola,V.;etal.RepeatedMeasurementsofCardiacBiomarkersinAtrialFibrillationandValidationoftheABCStrokeScoreOverTime.J.Am.HeartAssoc.2017,6,e004851.[CrossRef]102.Abramson,J.L.;Lewis,C.;Murrah,N.V.;Anderson,G.T.;Vaccarino,V.RelationofC-ReactiveProteinandTumorNecrosisFactor-AlphatoAmbulatoryBloodPressureVariabilityinHealthyAdults.Am.J.Cardiol.2006,98,649‚Äì652.[CrossRef]103.Simundic,A.-M.;Kackov,S.;Miler,M.;Fraser,C.G.;Petersen,P.H.TermsandSymbolsUsedinStudiesonBiologicalVariation:TheNeedforHarmonization.Clin.Chem.2015,61,438‚Äì439.[CrossRef]
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Biomolecules2021,11,1464
17of17
104.Khuseyinova,N.;Greven,S.;R√ºckerl,R.;Trischler,G.;Loewel,H.;Peters,A.;

---

### Chunk 4/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.520

anagementofPatientsWithBradycardiaand
CardiacConductionDelay[publishedonline
November6,2018].JAmCollCardiol.2018.doi:10.1016/j.jacc.2018.10.04436.WilliamsB,ManciaG,SpieringW,etal;ESCScientificDocumentGroup.2018ESC/ESH
GuidelinesfortheManagementofArterial
Hypertension.EurHeartJ.2018;39(33):3021-3104.doi:10.1093/eurheartj/ehy33937.Regitz-ZagrosekV,Roos-HesselinkJW,BauersachsJ,etal;ESCScientificDocumentGroup.

---

### Chunk 5/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.518

0;56(25):e50-e103.doi:10.1016/j.jacc.2010.09.00133.EpsteinAE,DiMarcoJP,EllenbogenKA,etal;AmericanCollegeofCardiology/AmericanHeart
AssociationTaskForceonPracticeGuidelines
(WritingCommitteetoRevisetheACC/AHA/NASPE
2002GuidelineUpdateforImplantationofCardiac
PacemakersandAntiarrhythmiaDevices);
AmericanAssociationforThoracicSurgery;Society
ofThoracicSurgeons.ACC/AHA/HRS2008
GuidelinesforDevice-BasedTherapyofCardiac
RhythmAbnormalities.JAmCollCardiol.2008;51(21):e1-e62.doi:10.1016/j.jacc.2008.02.03234.GrundySM,StoneNJ,BaileyAL,etal.AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/
APhA/ASPC/NLA/PCNAGuidelineonthe
ManagementofBloodCholesterol[published
onlineNovember10,2018].JAmCollCardiol.2018.doi:10.1016/j.jacc.2018.11.00335.KusumotoFM,SchoenfeldMH,BarrettC,etal.ACC/AHA/HRSGuidelineontheEvaluationand
ManagementofPatientsWithBradycardiaand
CardiacConductionDelay[publishedonline
November6,2018].JAmCollCardiol.2018.doi:10.1016/j.jacc.2018.10.04436.WilliamsB,ManciaG,SpieringW,etal;ESCScientificDocument

---

### Chunk 6/30
**Article:** Aula Afonso Salgado - Sistema nervoso aut√¥nomo (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.516

## Avalia√ß√£o Funcional e Diagn√≥stico via Variabilidade da Frequ√™ncia Card√≠aca (VFC)

No eixo diagn√≥stico, Afonso apresenta a **variabilidade da frequ√™ncia card√≠aca (VFC)** como o principal **biomarcador funcional** da integridade do SNA. A VFC √© medida a partir de um eletrocardiograma simples e n√£o invasivo, analisando-se os intervalos entre batimentos (intervalos NN). As varia√ß√µes naturais desses intervalos refletem a flexibilidade neurocard√≠aca.

Segundo a defini√ß√£o adotada pela Associa√ß√£o Americana de Cardiologia, a VFC √© a **medida da fun√ß√£o neurocard√≠aca** resultante da intera√ß√£o reflexa entre cora√ß√£o e c√©rebro, fornecendo dados din√¢micos do estado do SNA. Afonso resume:

- **Alta variabilidade** ‚Üí alta atividade parassimp√°tica, melhor resili√™ncia, melhor progn√≥stico.  
- **Baixa variabilidade** ‚Üí baixa atividade parassimp√°tica, maior carga alost√°tica, pior progn√≥stico.

Ele introduz dois conceitos centrais:

1.

---

### Chunk 7/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.499

olisA,McMurrayJ,PonikowskiP,RosenhekR,Ruschitzka
F,SavelievaI,SharmaS,SuwalskiP,
TamargoJL,TaylorCJ,vanGelderIC,VoorsAA,WindeckerS,ZamoranoJL,ZeppenfeldK.2016ESCguidelinesfor
themanagementofatrialbrillationde-velopedincollaborationwithEACTS.EurHeartJ.2016;37:2893‚Äì2962.2.YancyCW,JessupM,BozkurtB,ButlerJ,CaseyDEJr,DraznerMH,Fonarow
GC,GeraciSA,HorwichT,JanuzziJL,
JohnsonMR,KasperEK,LevyWC,MasoudiFA,McBrideP,McMurrayJ,MitchellJE,PetersonPN,RiegelB,Sam
F,StevensonLW,TangWH,TsaiEJ,
6A.M.Marraetal.ESCHeartFailure(2022)DOI:10.1002/ehf2.14117
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

WilkoffBL,AmericanCollegeofCardiol-ogyFoundation,AmericanHeartAssoci-ationTaskForceonPracticeGuidelines.2013ACCF/AHAguidelinefortheman-
agementofheartfailure:Areportof
theAmericanCollegeofCardiologyFoundation/AmericanHeartAssociationtaskforceonpracticeguidelines.JAmCollCardiol.2013;62:e147‚Äìe239.3.BealeAL,MeyerP,MarwickTH,

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.496

rhythmic therapy and/or catheter ablation 
Figure40|Strategiesforthediagnosisandmanagementofatrialbrillation.*Considerdoseadjustmentsnecessaryinpeoplewithchronickidneydisease(CKD).‚Ä†Thefollowinghasbeenrecommendedasastandardpackagefordiagnosticevaluationofnewatrialbrillation:(i)a12-leadelectrocardiogram(ECG)toestablishthediagnosis,assessventricularrate,andcheckforthepresenceofconductiondefects,ischemia,orstructuralheartdisease;(ii)laboratorytestingforthyroidandkidneyfunction,serumelectrolytes,andfullbloodcount;and(iii)
transthoracicechocardiographytoassessleftventricularsizeandfunction,leftatrialsize,forvalvulardisease,andrightheartsizeandfunction.
BP,bloodpressure;CHA2DS2-VASc,Congestiveheartfailure,Hypertension,Age$75(doubled),Diabetes,Stroke(doubled),Vasculardisease,Age65to74,andSexcategory(female);HAS-BLED,Hypertension,Abnormalliver/kidneyfunction,Strokehistory,Bleedinghistoryor
predisposition,Labileinternationalnormalizedratio(INR),Elderly,Drug/alcoholusage.

---

### Chunk 9/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.494

638(45)2,472(50)1,084(52)1,388(48)2,166(40)862(42)1,304(39)Calcium-channelblocker1,977(19)921(19)397(19)524(18)1,056(19)412(20)644(19)Nicorandil645(6)303(6)149(7)154(5)342(6)174(8)168(5)
Ivabradine146(1)68(1)25(1)43(1)78(1)33(1)45(1)
Spironolactone450(4)201(4)82(4)119(4)249(4)113(5)136(4)Electrocardiographicresults¬ßNormal2,672(34)1,366(36)513(36)853(36)1,306(32)479(34)827(30)
Myocardialischemia2,510(32)1,023(27)342(24)681(28)1,487(36)445(32)1,042(38)ST-segmentelevation998(13)329(9)90(6)239(10)669(16)174(12)495(18)ST-segmentdepression1,328(17)583(16)226(16)357(15)745(18)234(17)511(18)
T-waveinversion1,277(16)640(17)252(17)388(16)637(15)232(16)405(15)Physiologicalparameters¬ßHeartrate,beats/min8626882788278826842685258326Systolicbloodpressure,mmHg13929141301402914130137281362813728GRACEriskscore14338147361483414738140391393814040HematologicandclinicalchemistrymeasurementsHemoglobin,g/l13125125241242412623137251362513725eGFR,ml/min47164616471646164915491

---

### Chunk 10/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.485

diseasedurationandlowdensitylipoproteincholesterollevels.JAmCollCardiol
1996:28:573‚Äì579.50Pedersen&Saltin
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

CoakleyEH,RimmEB,ColditzG,KawachiI,WillettW.Predictorsofweightchangeinmen:resultsfrom
theHealthProfessionalsFollow-upStudy.IntJObesRelatMetabDisord1998:22:89‚Äì96.CoatsAJ,AdamopoulosS,MeyerTE,ConwayJ,SleightP.Effectsofphysicaltraininginchronicheartfailure.Lancet1990:335:63‚Äì66.CoatsAJ,AdamopoulosS,RadaelliA,McCanceA,MeyerTE,BernardiL,SoldaPL,DaveyP,OrmerodO,ForfarC.Controlledtrialofphysical
traininginchronicheartfailure.

---

### Chunk 11/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.479

ardpackagefordiagnosticevaluationofnewatrialbrillation:(i)a12-leadelectrocardiogram(ECG)toestablishthediagnosis,assessventricularrate,andcheckforthepresenceofconductiondefects,ischemia,orstructuralheartdisease;(ii)laboratorytestingforthyroidandkidneyfunction,serumelectrolytes,andfullbloodcount;and(iii)
transthoracicechocardiographytoassessleftventricularsizeandfunction,leftatrialsize,forvalvulardisease,andrightheartsizeandfunction.
BP,bloodpressure;CHA2DS2-VASc,Congestiveheartfailure,Hypertension,Age$75(doubled),Diabetes,Stroke(doubled),Vasculardisease,Age65to74,andSexcategory(female);HAS-BLED,Hypertension,Abnormalliver/kidneyfunction,Strokehistory,Bleedinghistoryor
predisposition,Labileinternationalnormalizedratio(INR),Elderly,Drug/alcoholusage.

---

### Chunk 12/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.475

from125to250pg/ml,whileforthoseover75years,itextendsfrom125to500pg/ml.Itiscrucialtoconductathoroughevaluationofpatientswithinthegreyzone,consideringfactorssuchasobesity,race-basedvariations,andongoingtreatment(asmanypatientswithahistory
ofhypertensionmayalreadybeondiuretics,renin‚Äìangiotensin
systeminhibitors,ormineralocorticoidreceptorantagonists).Intheoutpatientsetting,theextentofelevationinNPconcen-trationsatthetimeofheartfailurediagnosisiscloselylinkedtothe
riskofsubsequenthospitalizationandmortality.16Asaresult,therehasbeenasuggestiontoutilizeNT-proBNPconcentrationsatthe
timeofacommunity-basedheartfailurediagnosisasatriagingtooltoprioritizeaccesstoexpediteddiagnosticechocardiogra-phyandtosetupafollow-upplanforindividualswiththehighest
short-termriskofadverseevents.Theauthorsofthisconsensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwi

---

### Chunk 13/30
**Article:** Cardiologia VIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.469

# Cardiologia VIII

**Source:** https://web.plaud.ai/share/43b41764908850761::YXdzOnVzLXdlc3QtMg

---

## Reasoning Summary

## An√°lise de Exames, Fatores de Risco e Estrat√©gias Terap√™uticas em Cardiologia
### 1. Interpreta√ß√£o de Exames e Marcadores de Risco Cardiovascular
- **Princ√≠pio da Probabilidade e Contexto Cl√≠nico:** A an√°lise de exames laboratoriais deve seguir o princ√≠pio de que a medicina √© uma "ci√™ncia da probabilidade". Os valores devem ser interpretados dentro do contexto cl√≠nico do paciente (hist√≥ria, exame f√≠sico, idade) e n√£o como n√∫meros isolados a serem "corrigidos". √â crucial n√£o se fixar em atingir valores "√≥timos" em todos os exames, pois o exame √© um desfecho substituto e a prioridade √© o paciente como um todo.

---

### Chunk 14/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.469

co da dislipidemia.
- [ ] 2. Analisar criticamente os estudos sobre o Inclisiran (Cibrava), focando na diferen√ßa entre desfechos substitutos (redu√ß√£o de LDL) e desfechos cl√≠nicos duros (mortalidade, infarto, AVC).
- [ ] 3. Utilizar o site `the-nnt.com` para pesquisar o NNT e NNH de outros medicamentos prescritos na pr√°tica cl√≠nica.
- [ ] 4. Refletir sobre a influ√™ncia da ind√∫stria farmac√™utica e dos interesses financeiros na prescri√ß√£o de novos medicamentos.
- [ ] 5. Estudar a diferen√ßa entre risco relativo e risco absoluto para interpretar criticamente os achados de estudos cient√≠ficos.
- [ ] 6. Pesquisar sobre os diferentes tipos de √¥mega-3 (EPA, DHA, ALA) e suas formula√ß√µes para entender como a qualidade do suplemento afeta os resultados.
- [ ] 7. Investigar os exames de subfracionamento de LDL e a rela√ß√£o ApoA/ApoB como ferramentas de avalia√ß√£o de risco cardiovascular mais precisas que o LDL total.
- [ ] 8.

---

### Chunk 15/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.467

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 16/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.466

N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmitralowvelocity;E‚Ä≤,earlydiastolicmitralannularvelocity;TAPSE,tricuspidannularplaneexcursion;PASP,pulmonaryarterialsystolicpressure;RVOT-AT,rightventricularoutowtractaccelerationtime;VO2peak,peakoxygenconsumption;NYHA,NewYorkHeartAssociation;AF,atrialbrillation;ACE-I,angiotensin-converting-enzymeinhibitors;ARBs,angiotensin-receptorblockers;MRA,mineralocorticoid-receptorantagonist;ICD,implantablecardioverter-debrillator;CRT,cardiacresynchronizationtherapy;IGF-1D,IGF-1deciency;DHEA-SD,DHEA-Sdeciency.

---

### Chunk 17/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.465

or Holter ECG testingStep 2Prophylaxis againststroke and systemicthromboembolism
  (they are likely to have an increased CHA2DS2-VASc risk factor for stroke and are at high risk even with a score of 0‚Äì1)
  managed (e.g., alcohol advice, use of a proton pump inhibitor) Step 3Rate/rhythm control
‚Ä†‚Ä¢ Use medical therapy (e.g., beta blockade) to control ventricular rate to less than about 90 bpm at rest to decrease  symptoms and related complications‚Ä¢ For people with persistent symptoms despite adequate rate control, consider rhythm control with cardioversion,  antiarrhythmic therapy and/or catheter ablation 
Figure40|Strategiesforthediagnosisandmanagementofatrialbrillation.*Considerdoseadjustmentsnecessaryinpeoplewithchronickidneydisease(CKD).‚Ä†Thefollowinghasbeenrecommendedasastandardpackagefordiagnosticevaluationofnewatrialbrillation:(i)a12-leadelectrocardiogram(ECG)toestablishthediagnosis,assessventricularrate,andcheckforthepresenceofconductiondefects,ischemia,orstructuralhe

---

### Chunk 18/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.465

sensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwithamorethantwo-foldhigherriskofheartfailurehospitalizationand50%higherriskofmortalityascomparedwithanNT-proBNPof400‚Äì2000pg/ml.47Wesug-gestthat,irrespectiveofageandsex,patientswithanNT-proBNP
>2000pg/mlshouldbeprioritizedforechocardiographyandclini-calevaluationwithin2weeksofdiagnosis(Figure2).NT-proBNPinasymptomaticpatientswithriskfactors:heart
stressVariousriskfactors,suchashypertension,atheroscleroticcardio-vasculardisease,diabetes,obesity,andothers,contributetoanincreasedsusceptibilitytothedevelopmentofheartfailure.Intheabsenceofsymptomsofheartfailure,patientswithriskfactorsmay
exhibiteitherhearthealthorheartstress.Hearthealthrefersto
individualswhohaveastructurallynormalheartandnormalplasma
concentrationsofNPsandtroponins.¬©2023EuropeanSocietyofCardiology.

---

### Chunk 19/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.464

ngina/Non-ST-Elevation
MyocardialInfarction.JAmCollCardiol.2007;50(7):e1-e157.doi:10.1016/j.jacc.2007.02.01310.AmsterdamEA,WengerNK,BrindisRG,etal.2014AHA/ACCGuidelinefortheManagementof
PatientsWithNon-ST-ElevationAcuteCoronary
Syndromes:areportoftheAmericanCollegeof
Cardiology/AmericanHeartAssociationTaskForce
onPracticeGuidelines.JAmCollCardiol.2014;64(24):e139-e228.doi:10.1016/j.jacc.2014.09.01711.WheltonPK,CareyRM,AronowWS,etal.2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/
NMA/PcnaGuidelineforthePrevention,Detection,
Evaluation,andManagementofHighBlood
PressureinAdults:areportoftheAmericanCollege
ofCardiology/AmericanHeartAssociationTask
ForceonClinicalPracticeGuidelines.JAmCollCardiol.2018;71(19):e127-e248.doi:10.1016/j.jacc.2017.11.00612.StoutKK,DanielsCJ,AboulhosnJA,etal.AHA/ACCGuidelinefortheManagementofAdults
WithCongenitalHeartDisease:areportofthe
AmericanCollegeofCardiology/AmericanHeart
AssociationTaskForceonClinicalPractice
Guidelines[publishedonlineAugust10,2019].JAmCollCa

---

### Chunk 20/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** introduction | **Similarity:** 0.463

ontraindicationsThefollowingcontraindicationsareinagreementwithaEuropeanWorkingGroup(Gianuzzi&
Tavazzi2001).ÔøΩAcuteCHU(AMIorunstableangina),untilthe
conditionhasbeenstableforatleast5daysÔøΩDyspneaatrestÔøΩPericarditis,myocarditis,endocarditisÔøΩSymptomaticaorticstenosisÔøΩSeverehypertension.Thereisnoestablished,docu-
mentedborderlinebloodpressurevaluedeemedto
bethecut-offpointforincreasedrisk.Generallyit
isrecommendedthatdemandingphysicalexercise
beavoidedinthecaseofsystolicBP>180ordias-
tolicBP>105mmHgÔøΩFeverÔøΩSeriousnon-cardiacdiseaseHeartfailureBackgroundHeartfailureisaconditionwheretheheartisunabletopumpsufÔ¨ÅcientlytomaintainbloodÔ¨Çowtomeetthemetabolicneedsoftheperipheraltissue(Braun-
wald&Libby,2008).Heartfailureisaclinicalsyn-
dromewithsymptomssuchasÔ¨Çuidretention,
breathlessness,orexcessivetirednesswhenrestingor
exercising,andwithobjectivesymptomsofreduced
systolicfunctionoftheleftventricleatrest.Asymptomaticleftventriculardysfunctionisoftentheprecursorofthissyndrome.Sympt

---

### Chunk 21/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.462

:237‚Äì242.706.KnuutiJ,WijnsW,SarasteA,etal.2019ESCGuidelinesforthediagnosisandmanagementofchroniccoronarysyndromes.EurHeartJ.2020;41:407‚Äì477.707.MaronDJ,HochmanJS,ReynoldsHR,etal.Initialinvasiveorconservativestrategyforstablecoronarydisease.NEnglJMed.2020;382:1395‚Äì1407.707a.BangaloreS,MaronDJ,O‚ÄôBrienSM,etal.Managementofcoronarydiseaseinpatientswithadvancedkidneydisease.NEnglJMed.2020;382:1608‚Äì1618.708.JamesMT,HarBJ,TyrrellBD,etal.Effectofclinicaldecisionsupportwith
auditandfeedbackonpreventionofacutekidneyinjuryinpatients
undergoingcoronaryangiography:arandomizedclinicaltrial.JAMA.2022;328:839‚Äì849.709.HindricksG,PotparaT,DagresN,etal.Corrigendumto:2020ESC
GuidelinesforthediagnosisandmanagementofatrialbrillationdevelopedincollaborationwiththeEuropeanAssociationforCardio-
ThoracicSurgery(EACTS):theTaskForceforthediagnosisandmanagementofatrialbrillationoftheEuropeanSocietyofCardiology(ESC)DevelopedwiththespecialcontributionoftheEuropeanHeart
RhythmAssociation(EHRA)oftheESC.Eu

---

### Chunk 22/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.460

ions,opportunisticpulse-based
screening(e.g.,whentakingBP),followedbya12-lead
electrocardiogramifanirregularlyirregularpulseisidentiedshouldbeconsidered.Suchanapproachislowcostandsimpletoimplement.Figure40outlinesapproachestodifferentdiagnosticandmanagementstrategies.PracticePoint3.16.1:Followestablishedstrategiesforthediagnosisandmanagementofatrialbrillation(Figure40).Prophylaxisagainststrokeandsystemicthromboembolism.Recentcardiologyguidelinesrecommendariskfactor‚Äìbasedapproachtostrokethromboprophylaxisdecisionsinatrial
brillationusingtheCongestiveheartfailure,Hypertension,
Age$75(doubled),Diabetes,Stroke(doubled),Vasculardisease,Age65to74,andSexcategory(female)(CHA2DS2-VASc)strokeriskscore.Theyrecommendthatonlypeopleat
‚Äúlowstrokerisk‚Äù(CHA2DS2-VAScscore¬º0inmen,or1inwomen)shouldnotbeofferedantithrombotictherapy.Oral
anticoagulantsshouldbeconsideredforstrokeprevention
withaCHA2DS2-VAScscoreof1inmenor2inwomen,consideringnetclinicalbenetandvaluesandpreferencesofpeoplewithCKD.Or

---

### Chunk 23/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIV (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.458

- [ ] 2. Para pacientes com s√≠ndrome metab√≥lica, considerar estrat√©gia Mediterr√¢nea organizada; preferir vers√£o com restri√ß√£o cal√≥rica combinada com atividade f√≠sica, monitorando resultados aos 6 e 12 meses.
- [ ] 3. Solicitar perfil lip√≠dico ampliado em casos selecionados: HDL, triglicer√≠deos, insulina, PCR, LDL oxidado e, quando indicado, subfracionamento de LDL; evitar decis√µes baseadas apenas em LDL total.
- [ ] 4. Planejar exames de risco cardiovascular conforme necessidade: score de c√°lcio coronariano e angiotomografia de coron√°rias (incluindo avalia√ß√£o de placas moles) quando o contexto cl√≠nico justificar.
- [ ] 5. Revisar e atualizar protocolos internos sobre √°lcool: remover recomenda√ß√µes de consumo ‚Äúcardioprotetor‚Äù; educar pacientes sobre riscos de c√¢ncer e piora do sono; avaliar predisposi√ß√£o/sensibilidade individual.
- [ ] 6.

---

### Chunk 24/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.457

congestiveheartfailureinanurgent-caresetting.JAmCollCardiol2001;37:379‚Äì385.https://doi.org/10.1016/s0735-1097(00)01156-619.CollinsSP,LindsellCJ,StorrowAB,AbrahamWT;ADHEREScienticAdvisoryCommittee,InvestigatorsandStudyGroup.Prevalenceofnegativechestradio-graphyresultsintheemergencydepartmentpatientwithdecompensatedheart
failure.AnnEmergMed2006;47:13‚Äì18.https://doi.org/10.1016/j.annemergmed.2005.04.00320.Bay√©s-Gen√≠sA,Santal√≥-BelM,Zapico-Mu√±izE,L√≥pezL,CotesC,BellidoJ,etal.N-terminalprobrainnatriureticpeptide(NT-proBNP)intheemergencydiagnosisandin-hospitalmonitoringofpatientswithdyspnoeaandventriculardysfunction.EurJHeartFail2004;6:301‚Äì308.https://doi.org/10.1016/j.ejheart.2003.12.01321.LamLL,CameronPA,SchneiderHG,AbramsonMJ,M√ºllerC,KrumH.Meta-analysis:EffectofB-typenatriureticpeptidetestingonclinicaloutcomes
inpatientswithacutedyspneaintheemergencysetting.AnnInternMed2010;153:728‚Äì735.https://doi.org/10.7326/0003-4819-153-11-201012070-0000622.MoeGW,HowlettJ,JanuzziJL,ZowallH

---

### Chunk 25/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.455

tteronbaselineECG.46Thefol-lowingsuggestedmodicationsforcomorbidconditionsarebased
moreonexpertopinionratherthanonstrongevidenceandshould
berenedasmoreinformationbecomesavailable.WheneGFRis<30ml/min/1.73m2,thecut-pointforNT-proBNPshouldbeincreasedby35%;foreGFRbetween30and45ml/min/1.73m2by25%andforeGFR45-60ml/min/1.73m2by15%.WhenBMIisbetween30and35kg/m2,theNT-proBNPcut-offshouldbereducedby25%;forBMIbetween35and40kg/m2by30%andover40kg/m2by40%.Foratrialbrillationorutter,theNT-proBNPcut-pointshouldbeincreasedby50%whentheventricularrate
is90bpmatthetimeoftheblooddraworby100%whentheventricularrateis>90bpm.Furtherinvestigationisrequiredtoascertainwhichofthetwoapproaches,thesimplerage-adjustedorthemoresophisticatedfullyadjustedrule-incut-points,offeragreaterreductioninunnec-
essaryreferralsandechocardiograms.........................................................................................................................................................................

---

### Chunk 26/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.454

o cr√¥nica.
    -   Lipoprote√≠na (a) elevada, um fator de risco gen√©tico pr√≥-tromb√≥tico e pr√≥-inflamat√≥rio.
    -   Desequil√≠brios hormonais (baixo estrog√™nio e testosterona), especialmente na menopausa.
-   **Diagn√≥stico Suspeito:** Nenhum no momento
## Plano:
-   **Prescri√ß√£o:** Inserir mais aqui
-   **Pr√≥ximos Passos/Exames:**
    -   O palestrante defende uma avalia√ß√£o abrangente que vai al√©m dos fatores de risco cl√°ssicos, incluindo:
    -   Dosagem das propor√ß√µes de √îmega-3 e √îmega-6 (√çndice √îmega-3).
    -   Medi√ß√£o do Horm√¥nio D (Vitamina D), com metas de n√≠veis √≥timos (ex: >80 ng/mL para cardiopatas, controlando com PTH).
    -   Curva glic√™mica e de insulina para detectar resist√™ncia √† insulina precocemente.
    -   Avalia√ß√£o da homociste√≠na.
    -   Medi√ß√£o da lipoprote√≠na (a).
    -   Avalia√ß√£o da rela√ß√£o ApoB/ApoA.
    -   Avalia√ß√£o dos n√≠veis hormonais (testosterona, estradiol, DHEA).

---

### Chunk 27/30
**Article:** Cardiologia VIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.453

6 atrav√©s de fitoqu√≠micos (ch√°s, shots) e jejum intermitente.
- [ ] 7. Abandonar a recomenda√ß√£o de consumo moderado de √°lcool, educando os pacientes sobre seus riscos metab√≥licos, gen√©ticos e sobre a qualidade do sono.
- [ ] 8. Estudar e ter em m√£os os estudos que embasam a abordagem funcional para argumentar contra dogmas m√©dicos estabelecidos, encaminhando a outros profissionais quando necess√°rio.
- [ ] 9. Ficar atento √†s aulas do Dr. T√∫lio Sperber, que complementar√£o o conte√∫do deste m√≥dulo de cardiologia.

---

## Teaching Note

Data e Hora: 2025-11-20 20:42:21
Local: [Inserir Local]
Aula: [Inserir Nome da Aula]: M√≥dulo de Cardiologia
## Vis√£o Geral
A aula abordou a interpreta√ß√£o de exames laboratoriais e marcadores gen√©ticos na cardiologia, enfatizando a individualiza√ß√£o do tratamento em detrimento do foco exclusivo em valores de refer√™ncia.

---

### Chunk 28/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.452

T-proBNP,N-terminalpro-B-typenatriureticpeptide;T2D,type2diabetes.........................................................................................................................................................................(e.g.dietarysaltintake,exercise,smoking,etc.)andthetreatmentofriskfactorssuchashypertension.NT-proBNPconcentrationsmaybere-evaluatedwithinthefollowing6‚Äì12monthstodeter-minetheresponsetoanyinterventionandtheneedforfurtherinvestigation(Figure3).Thisadvice,basedonaconsensusdecision,requiresconrmationbyprospectivestudies.Itisimportanttoval-idatetheheartstressalgorithmusingclinicaltrialdata;conductingpost-hocvalidationshouldbefeasiblefromexistingtrialdataor
registries(suchastheUKBiobank).FIND-HF‚ÄìTheHFAacronymforearlydiagnosisofheartfailureTopromoteearlydiagnosisofheartfailureandassisthealthcareprofessionalsandpatients,wesuggestthemnemonicacronymFIND-HF(Fatigue,Increasedwateraccumulation,Natriureticpep-tidetesting,andDyspnoea-HeartFailure),whichservesasa
re

---

### Chunk 29/30
**Article:** Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.451

sinus tachycardia, atrial flutter, atrial fibrillation, palpitation, and high burden of ventricular ectopy. Chest pain, palpitation, and impaired pulmonary diffusion capacity after six months are common cardiopulmonary symptoms of long Covid (
8
, 
72
, 
105
). Individuals with long Covid may have abnormalities on cardiac imaging tests, such as echocardiography or MRI, even if they do not have cardiac symptoms in the acute setting (
106
).
Zadeh et al.Page 12
Arch Microbiol Immunol. Author manuscript; available in PMC 2023 June 29.
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Mechanisms of cardiovascular disease
I.
 
Direct invasion of cardiomyocytes: 
 Covid-19 can directly infect the heart through 
the ACE2 receptors (
8
).

---

### Chunk 30/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.451

3‚Äì815.https://doi.org/10.1002/ejhf.147124.MuellerC,ScholerA,Laule-KilianK,MartinaB,SchindlerC,BuserP,etal.UseofB-typenatriureticpeptideintheevaluationandmanagementofacutedyspnea.NEnglJMed2004;350:647‚Äì654.https://doi.org/10.1056/NEJMoa03168125.SiebertU,MilevS,ZouD,LitkiewiczM,GagginHK,TirapelleL,etal.EconomicevaluationofanN-terminalproB-typenatriureticpeptide-supporteddiagnos-ticstrategyamongdyspneicpatientssuspectedofacuteheartfailureinthe
emergencydepartment.AmJCardiol2021;147:61‚Äì69.https://doi.org/10.1016/j.amjcard.2021.01.03626.MuellerC,Laule-KilianK,SchindlerC,KlimaT,FranaB,RodriguezD,etal.Cost-effectivenessofB-typenatriureticpeptidetestinginpatientswithacutedys-pnea.ArchInternMed2006;166:1081‚Äì1087.https://doi.org/10.1001/archinte.166.10.108127.JanuzziJL,vanKimmenadeR,LainchburyJ,Bayes-GenisA,Ordonez-LlanosJ,Santalo-BelM,etal.NT-proBNPtestingfordiagnosisandshort-termprognosisinacutedestabilizedheartfailure:Aninternationalpooledanalysisof1256patients:TheInternationalCollabor

---

